BioNeutral Group, Inc. Enters Sales And Distribution Agreement With Nyco Products Co.

Publishing & Media

Share Tweet

BioNeutral Group, Inc. Enters Sales And Distribution Agreement With Nyco Products Co.

BioNeutral Group, Inc. (OTCPINK: BONU) saw its share volume skyrocket on June 11th with 683,950,452 shares exchanging hands, 11 times higher than its three month daily average volume of 62,332,061 shares.

This uptick in volume comes after BioNeutral Group, Inc. announced today that it has entered into a Sales and Distribution Agreement with Nyco Products Co. in Countryside, Illinois, to distribute BioNeutral's YGIENE(tm) 206 Sterilant for advanced infection control. Nyco is a respected manufacturer and distributor of cleaners, disinfectants and sanitizers for janitorial, hospitality, long-term care, MRO, and food service. YGIENE(tm) 206 adds a superior level of infection control to Nyco's product offering in these markets.

The partnership between Nyco and BioNeutral will be advantageous for customers of both companies. YGIENE(tm) 206 brings additional efficacy in infection control to Nyco's product offering, while Nyco provides exceptional support in sales and customer training, plus critical exposure to a national distribution network for BioNeutral. According to Ray Dunning, Sr. Vice President of Sales for BioNeutral, "Nyco's ability to offer us direct and immediate national access to long term health care markets and other specialty channels is extremely attractive. Without question, Nyco is the type of company with whom we want to be associated. Their commitment to innovation in cleaning and disinfecting along with their industry leadership and longevity make them an ideal distributor partner for BioNeutral."

"We're very excited to team up with BioNeutral to be able to offer our customers amazing solutions that have the potential to reduce healthcare associated infections (HAIs) in hospitals and other healthcare facilities," stated Bob Stahurski, President and CEO of Nyco Products Company. "A one-step non-chlorine bleach alternative sterilant that kills all mircoorganisms within 20 minutes could highly impact disinfection procedures and protocols for the healthcare market. One key reason we chose to partner with BioNeutral is because YGIENE(tm) 206 does not have the adverse patient reactions associated with chlorine and bleach based products."

BONU closed the day at $.0004, 100% higher than its previous close of $.0002. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

DRIO Sees Share Volume Continue Upward Trend

LabStyle Innovations Corp. (OTCQB: DRIO) saw its share volume saw its share volume continue to rise on June 11th with 295,826 shares exchanging hands, more than four time higher than its three month daily average volume of 72,861 shares.

LabStyle Innovations, developer of the Dario(tm) Diabetes mHealth Solution, announced on Monday that the June 5th presentation from President and Chief Executive Officer, Mr. Erez Raphael, is now available for on-demand viewing at

Since 2010,, created by BetterInvesting, PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

LabStyle Innovations Corp. develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario(tm) personalized Diabetes mHealth Solution. Dario(tm) received CE mark certification in September 2013 and began a world rollout of the Dario(tm) mobile application in select countries in December 2013, and initial launches of the full Dario(tm) solution have commenced in Europe, Australia and New Zealand during 2014.  LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario(tm) smart meter (Dario(tm) Blood Glucose Monitoring System) in December 2013.  LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services, and in April 2014 LabStyle received a Notice of Allowance for a U.S. patent covering core functions of the Dario(tm) Blood Glucose Monitoring System.

DRIO closed the day at $1.25, 21.36% higher than its previous close of $1.03. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

Advanced Cell Technology Sees Share Volume Remain Strong

Advanced Cell Technology Inc. (OTCQB: ACTC) saw its share volume remain strong on June 11th with 9,889,206 shares exchanging hands, right on par with its three month daily average of 9,986,011 shares.

Advanced Cell Technology, Inc., (ACT) is a Marlborough, Massachusetts based biotechnology company focused on the development and commercialization of human embryonic stem cell (hESC) and adult stem cell technology. The company's most advanced products are in clinical trials for the treatment of dry age-related macular degeneration and Stargardt's macular degeneration. These cell therapies are also clinical trial candidates for the treatment of myopic macular degeneration. ACT's preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company's intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.

ACTC closed the day at $.0569. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

ABOUT US: issues momentum alerts on stocks that can provide gains to day traders. provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the newsletter and receiving alerts from a Pro-Active team of researchers. believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:

Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.